Prenatal maternal COVID-19 vaccination and pregnancy outcomes

Wainstock, Tamar; Yoles, Israel; Sergienko, Ruslan; Sheiner, Eyal

doi:10.1016/j.vaccine.2021.09.012

Cited by 129 publications

(196 citation statements)

References 16 publications

Supporting

Mentioning

178

Contrasting

Unclassified

Order By: Relevance

“…There were no severe local or generalised complications or severe maternal or foetus related pregnancy complications in our study's pregnancy group. An increasing number of studies have confirmed the safety of COVID-19 vaccination in pregnant women [16][17][18], and other studies have also confirmed the good tolerability of the BNT162b2 mRNA COVID-19 vaccine in the general population [19,20]. Our findings showed that the safety and tolerability of COVID-19 vaccination during pregnancy holds true for the Polish population.…”

Section: Discussionsupporting

confidence: 78%

Tolerability of the BNT162b2 COVID-19 Vaccine during Pregnancy among Polish Healthcare Professionals

et al. 2022

View full text Add to dashboard Cite

The tolerance and safety of vaccination in pregnancy should be assessed in local populations based on ethnic differences across countries. Therefore, this study aimed to determine the tolerability of the BNT162b2 mRNA vaccination in pregnancy in a Polish population. An online questionnaire enquiring about the safety and tolerability of the BNT162b2 mRNA vaccine was distributed to pregnant and non-pregnant female healthcare professionals who had voluntarily received one or two doses of the COVID-19 vaccine in Poland. The two groups were compared simultaneously considering the COVID-19 infection status before vaccination. Compared with that noted in the control group, pregnant women in the COVID-19-free group were less likely to have fever (p = 0.002) or gastrointestinal symptoms (p = 0.009) after the second dose. In the COVID-19-exposed group, pregnant women were less likely to experience local skin reactions (p = 0.009), and myalgia (p = 0.003) after the first dose. After the second dose, the only noticeable difference was a lower incidence of myalgia (p = 0.001) in pregnant women. The tolerability of the BNT162b2 mRNA COVID-19 vaccine was similar in both the groups. No severe local, generalised, or pregnancy complications related to mother or foetus were observed. Good tolerability of the BNT162b2 mRNA COVID-19 vaccine in pregnancy in the Polish population may facilitate the decision to vaccinate pregnant women against COVID-19.

show abstract

Section: Discussionsupporting

confidence: 78%

Tolerability of the BNT162b2 COVID-19 Vaccine during Pregnancy among Polish Healthcare Professionals

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Concerns among pregnant women regarding vaccine safety are a persistent barrier to vaccine acceptance during pregnancy. Previous studies of maternal COVID-19 vaccination and birth outcomes have been limited by small sample size (2) or lack of an unvaccinated comparison group (3). In this retrospective cohort study of live births from eight Vaccine Safety Datalink (VSD) health care organizations, risks for preterm birth (<37 weeks' gestation) and small-for-gestational-age (SGA) at birth (birthweight <10th percentile for gestational age) after COVID-19 vaccination (receipt of ≥1 COVID-19 vaccine doses) during pregnancy were evaluated.…”

mentioning

confidence: 99%

Receipt of COVID-19 Vaccine During Pregnancy and Preterm or Small-for-Gestational-Age at Birth — Eight Integrated Health Care Organizations, United States, December 15, 2020–July 22, 2021

Lipkind¹,

Vazquez‐Benitez²,

DeSilva³

et al. 2022

MMWR Morb. Mortal. Wkly. Rep.

178

188

View full text Add to dashboard Cite

“…Wainstock et al reported on a cohort of 4399 pregnant women out of which 913 (20.6%) received either one or two vaccines during pregnancy. No differences were found between groups in pregnancy, delivery and fetal outcomes [ 10 ]. In another study, data on 1328 pregnant women of whom 140 received at least one dose of the SARS-CoV-2 vaccine were presented showing no adverse maternal or fetal outcomes in the vaccinated group [ 11 ].…”

Section: Discussionmentioning

confidence: 99%

“…Several studies have demonstrated the safety of SARS-CoV-2vaccine in pregnancy, showcasing a protective effect from symptomatic disease, with minimal adverse neonatal outcomes [ 10 – 13 ]. Moreover, some studies have suggested that maternal vaccination may induce offspring immunity against SARS-CoV-2 [ 14 , 15 ].…”

Section: Introductionmentioning

confidence: 99%

Safety of SARS-CoV-2 vaccination during pregnancy- obstetric outcomes from a large cohort study

Dick

Rosenbloom

Gutman-Ido

et al. 2022

BMC Pregnancy Childbirth

View full text Add to dashboard Cite

Background COVID-19 during pregnancy is associated with adverse outcomes for mother and fetus. SARS-CoV-2 vaccination has significantly reduced the risk of symptomatic disease. Several small studies have reported the safety of SARS-CoV-2 vaccination during pregnancy, with no adverse effect on obstetric outcomes. Objective To examine the association between SARS-CoV-2 vaccination during pregnancy and maternal and neonatal outcomes in a large cohort study. Furthermore, to evaluate if timing of vaccination during pregnancy is related to adverse outcomes. Methods A retrospective cohort study of women who delivered between December 2020 and July 2021 at a large tertiary medical center. Excluded were women with multiple pregnancy, vaccination prior to pregnancy, COVID-19 infection during or before pregnancy, or unknown timing of vaccination. Primary outcomes were the incidence of preterm labor and of small for gestational age. Secondary outcomes were other maternal and neonatal complications. A secondary analysis investigating the association between time of vaccination and outcomes was also performed. Multivariable logistic regression models were used to adjust for potential confounders. Results There were 5618 women who met the inclusion criteria: 2,305 (41%) women were vaccinated and 3,313 (59%) were unvaccinated. There were no differences between vaccinated and non-vaccinated patients with respect to primary outcomes. The rate of preterm birth was 5.5% in the vaccinated group compared to 6.2% in the unvaccinated group (p = 0.31). Likewise, the rates of small for gestational age were comparable between the two groups (6.2% vs. 7.0% respectively, p = 0.2). In a secondary analysis focusing on time of vaccination and its relationship with outcomes, patients vaccinated in the second trimester (n = 964) and in the third trimester (n = 1329) were independently compared to their unvaccinated counterparts. Women who were vaccinated in the second trimester were more likely to have a preterm birth (8.1% vs. 6.2%, p < 0.001). This association persisted after adjusting for potential confounders (adjusted odds ratio 1.49, 95%CI 1.11, 2.01). Conclusions SARS-CoV-2 vaccine appears to be safe during pregnancy with no increase in incidence of preterm labor and small for gestational age compared to unvaccinated women. However, in women vaccinated during the second trimester there may be an increase in the rate of preterm birth.

show abstract

Prenatal maternal COVID-19 vaccination and pregnancy outcomes

Cited by 129 publications

References 16 publications

Tolerability of the BNT162b2 COVID-19 Vaccine during Pregnancy among Polish Healthcare Professionals

Tolerability of the BNT162b2 COVID-19 Vaccine during Pregnancy among Polish Healthcare Professionals

Receipt of COVID-19 Vaccine During Pregnancy and Preterm or Small-for-Gestational-Age at Birth — Eight Integrated Health Care Organizations, United States, December 15, 2020–July 22, 2021

Safety of SARS-CoV-2 vaccination during pregnancy- obstetric outcomes from a large cohort study

Contact Info

Product

Resources

About